(HLNLN; Baa1 Pos/BBB+)
Not sure what is sterling markets are doing on the Haleon/Reckitt spread (below).
Haleon €30s (were) a value view for us starting in June last year after it followed Reckitt wider on a index sell-off (Reckitt high beta then on its litigation woes). Its -30bps in since (vs. €IG -7) and completely reversed the Reckitt/Haleon spread - something we think will continue to move in that direction; Reckitt is still yet to settle bulk federal lawsuits and has tabled 30% of its business for sale with unch leverage through it. Meanwhile Haleon is running mid-single digit organic sales growth, HSD organic EBIT growth and continues to delever post its split from GSK in 2022 (4x to 2.9x, target 2.5x).
Yet sterling markets has sent the spread in the opposite direction (Haleon 33s/Reckitt 32; both 2024 issuances). We do think it is the Haleon 33s that are mispriced/wide vs. broader comps.
FY results; Haleon 27th Feb, Reckitt 6th March.

Find more articles and bullets on these widgets:
The ECB’s December 2024 SESFOD survey (Survey on credit terms and conditions in euro-denominated securities financing and OTC derivatives markets) reports a tightening in credit terms and conditions between September and November 2024 “as general market liquidity deteriorated”.
For the full preview including summaries of a dozen sellside views click here.